Cardiac Surgery Infections

Benefits

Risks & contraindications

Interactions

Other

Highlighted claims

• Antibiotics administered during surgery reduce SSI and other healthcare-associated infection risk. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
• Surgical site infections complicate about 8% of cardiac surgery operations, while other healthcare-associated infections complicate about 15%. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
• Surgical site infections after cardiac surgery are associated with substantial suffering and mortality rates reported as high as 20%. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
• C. difficile healthcare-associated infections are increasing and are directly linked to antimicrobial exposure. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol
• In cardiac surgery patients in the United States, C. difficile infections cost at least US$212 million each year. — Multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (CALIPSO): trial protocol